About NBR“Nightly Business Report produced by CNBC” (NBR) is an award-winning and highly-respected nightly business news program that airs on public television. Television’s longest-running evening business news broadcast, “NBR” features in-depth coverage and analysis of the biggest financial news stories of the day and access to some of the world’s top business leaders and policy makers.
NBR on TwitterMy Tweets
NBR Staff’s Posts
Tonight on Nightly Business Report, stocks end the week lower, but will a jam-packed economic agenda next week change sentiment? And, why Sovaldi, the breakthrough Hepatitis C drug, is creating a big headache for both states and health insurers.
Today’s stock stories: LOCO, SWK, ABBV, XRX, SWFT & DAL.
Home builders got hammered last month. What’s ailing the housing market?
Ford and GM posted earnings today that shows two automakers on two very different roads.
Mixed economic data along with a mixed bag of earnings kept stocks trading in a narrow range all day.
Tonight: President Obama lays out his plan to close a tax loophole that some companies are taking advantage of to save billions of dollars. Did the President make the case?
President Obama lays out his plan to close a tax loophole that some companies are taking advantage of to save billions of dollars. Did the President make the case? Find out tonight on Nightly Business Report.
Today’s stock stories: FB, BMY, LLY, V, MMM, DKDN, SBUX, BIDU, Z & TRLA.
The Securities and Exchange Commission voted to end a long-time staple of the investment industry today: the fixed $1 a share price for money market mutual funds, in order to keep that $2.3 trillion market safe in the event of another financial crisis.
Why are shares of Delta flying high and shares of Boeing falling, despite strong earnings?
AT&T reported earnings that missed estimates. How is the telecom sector doing as a whole and it is worth your investment dollars?
Shares of Puma Biotechnology gained roughly 300 percent, on positive results of an experimental breast cancer drug in a late stage trial. Biogen Idec saw its shares climb on surging sales of its new multiple sclerosis drug. What’s behind the numbers at Puma and Biogen Idec and what can investors look forward to?
Tonight: A biotech stock soars 300% in one day. What’s behind the move higher?
Tonight on Nightly Business Report, a biotech stock soars 300% in one day. What’s behind the move higher? And, will the SEC’s new rules governing money market funds impact individual investors?
Today’s stock stories: PEP, GSK, DOW, XLNX & CAT